- Home
- IDN vs APLT Comparison
IDN vs APLT Comparison
Compare IDN & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDN
- APLT
- Stock Information
- Founded
- IDN 1994
- APLT 2016
- Country
- IDN United States
- APLT United States
- Employees
- IDN N/A
- APLT N/A
- Industry
- IDN Computer Software: Prepackaged Software
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- IDN Technology
- APLT Health Care
- Exchange
- IDN Nasdaq
- APLT Nasdaq
- Market Cap
- IDN 46.8M
- APLT 37.5M
- IPO Year
- IDN 1999
- APLT 2019
- Fundamental
- Price
- IDN $2.83
- APLT $0.40
- Analyst Decision
- IDN Buy
- APLT Buy
- Analyst Count
- IDN 2
- APLT 7
- Target Price
- IDN $3.00
- APLT $6.10
- AVG Volume (30 Days)
- IDN 47.0K
- APLT 1.9M
- Earning Date
- IDN 05-13-2025
- APLT 05-20-2025
- Dividend Yield
- IDN N/A
- APLT N/A
- EPS Growth
- IDN N/A
- APLT N/A
- EPS
- IDN N/A
- APLT N/A
- Revenue
- IDN $19,997,000.00
- APLT $455,000.00
- Revenue This Year
- IDN $7.60
- APLT $1,768.13
- Revenue Next Year
- IDN $10.02
- APLT $361.28
- P/E Ratio
- IDN N/A
- APLT N/A
- Revenue Growth
- IDN 5.77
- APLT N/A
- 52 Week Low
- IDN $1.92
- APLT $0.30
- 52 Week High
- IDN $4.46
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- IDN 61.62
- APLT 46.92
- Support Level
- IDN $2.47
- APLT $0.39
- Resistance Level
- IDN $2.87
- APLT $0.44
- Average True Range (ATR)
- IDN 0.17
- APLT 0.04
- MACD
- IDN 0.03
- APLT 0.01
- Stochastic Oscillator
- IDN 92.86
- APLT 45.49
About IDN Intellicheck Inc.
Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The products of the company include solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.